Obesity: Drugs
(asked on 21st July 2025) - View Source
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 21 July 2025 to Question 67568 on Obesity: Drugs, what estimate her Department has made of the number of adverse health incidents associated with weight loss medications obtained through online private providers in the last 12 months.
The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for ensuring medicines, medical devices, and blood components for transfusion meet applicable standards of safety, quality, and efficacy. The MHRA rigorously assesses available data, including from the Yellow Card scheme, and seeks advice from their independent advisory committee, the Commission on Human Medicines, where appropriate to inform regulatory decisions.
Information collected via the Yellow Card scheme in relation to where the medicine was obtained cannot differentiate private providers specifically. A question regarding where the patient obtained their medicine is included on a Yellow Card report, however this is not mandatory and is a free text field. This free text information is therefore available to support signal detection and assessment, but cannot be extracted or analysed in an aggregated format.
The MHRA publishes data received via the Yellow Card scheme in the form of interactive Drug Analysis Profiles (iDAPs). These interactive profiles display a complete listing of all suspected adverse drug reactions (ADRs) that have been reported to the MHRA via the Yellow Card scheme for particular drug substances. This includes all reports received from healthcare professionals, members of the public, and pharmaceutical companies. On iDAPS it’s possible to find information for several different data points such as the number of ADR reports by year, age, and sex, as well as information on the types of reactions included in the reports. Guidance concerning the interpretation of the information included is provided at the bottom of each iDAP page. It is particularly important to note that reports are not confirmed side effects to a medication, and that incidence cannot be derived since a number of factors influence the reporting of ADRs. Further information on iDAPs is available at the following link: